Biopharmaceutical developer Immunomedics posted revenues of $2 million for the first quarter of 2001 (end-September 30), up slightly from the $1.4 million in revenues reported for the same period last year. At the same time, the Morris Plains, NJ-based company's net loss for the quarter was $1.5 million, compared with $2.2 million for the first quarter of fiscal 2000.
Immunomedics chairman and CEO Dr. David Goldberg said he was pleased with the company's progress in developing a phase III trial for its non-Hodgkin's lymphoma therapeutic antibody, epratuzumab, while continuing to control costs.
By AuntMinnie.com staff writersNovember 7, 2000
Relating Reading
Immunomedics revenues slide in 2000, August 17, 2000
Immunomedics turns in flat Q3, May 15, 2000
Immunomedics raises $37.2 million, February 18, 2000
Copyright © 2000 AuntMinnie.com
